BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 14723254)

  • 1. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
    Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
    J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study.
    de la Cámara R; Figuera A; Sureda A; Hermida G; Verge G; Olalla I; Fernández Rañada JM; Domingo Albos A
    Haematologica; 1997; 82(6):668-75. PubMed ID: 9580087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
    Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
    J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey.
    Akova M; Akan H; Korten V; Biberoğlu K; Hayran M; Unal S; Kars A; Kansu E
    Int J Antimicrob Agents; 1999 Sep; 13(1):15-9. PubMed ID: 10563400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia.
    Serefhanoglu K; Ersoy Y; Serefhanoglu S; Aydogdu I; Kuku I; Kaya E
    Ann Acad Med Singap; 2006 Jan; 35(1):11-6. PubMed ID: 16470268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.
    Cometta A; Calandra T; Gaya H; Zinner SH; de Bock R; Del Favero A; Bucaneve G; Crokaert F; Kern WV; Klastersky J; Langenaeken I; Micozzi A; Padmos A; Paesmans M; Viscoli C; Glauser MP
    Antimicrob Agents Chemother; 1996 May; 40(5):1108-15. PubMed ID: 8723449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
    Behre G; Link H; Maschmeyer G; Meyer P; Paaz U; Wilhelm M; Hiddemann W
    Ann Hematol; 1998 Feb; 76(2):73-80. PubMed ID: 9540761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors.
    Düzova A; Kutluk T; Kanra G; Büyükpamukçu M; Akyüz C; Seçmeer G; Ceyhan M
    Turk J Pediatr; 2001; 43(2):105-9. PubMed ID: 11432485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial.
    Feld R; DePauw B; Berman S; Keating A; Ho W
    J Clin Oncol; 2000 Nov; 18(21):3690-8. PubMed ID: 11054442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer.
    Fleischhack G; Hartmann C; Simon A; Wulff B; Havers W; Marklein G; Hasan C; Bode U
    J Antimicrob Chemother; 2001 Jun; 47(6):841-53. PubMed ID: 11389117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever.
    Engervall P; Günther G; Ljungman P; Lönnqvist B; Hast R; Stiernstedt G; Kalin M; Ringertz S; Bjökholm M
    Scand J Infect Dis; 1996; 28(3):297-303. PubMed ID: 8863366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer.
    Chuang YY; Hung IJ; Yang CP; Jaing TH; Lin TY; Huang YC
    Pediatr Infect Dis J; 2002 Mar; 21(3):203-9. PubMed ID: 12005083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
    Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of fever in neutropenic patients with acute leukemia: current role of ceftazidime plus amikacin as empiric therapy.
    Fanci R; Paci C; Martinez RL; Fabbri A; Pecile P; Leoni F; Longo G
    J Chemother; 2000 Jun; 12(3):232-9. PubMed ID: 10877519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors.
    Kebudi R; Görgün O; Ayan I; Gürler N; Akici F; Töreci K
    Med Pediatr Oncol; 2001 Apr; 36(4):434-41. PubMed ID: 11260566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
    Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
    Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients.
    Vandercam B; Gérain J; Humblet Y; Ferrant A; Wauters G; Moreau M; Longueville J; Symann M; Straetmans N
    Ann Hematol; 2000 Mar; 79(3):152-7. PubMed ID: 10803938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.